Additional file 3 of Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis

Additional file 3. Experimental data. Skin fibrosis reduced after administering mASCs. 1×105 mASCs administration significantly reduced dermal thickness (distance between epidermal–dermal junction and dermal–fat junction) and hydroxyproline content. n = 6 in each group. Data are presented as mean ± SEM. **P < 0.01. ***P < 0.005 vs. BLM-alone group

Additional file 2 of Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis

Additional file 2. Experimental data. Genes of GREM-1 and IL-6 were not affected by hep-ASCs. For the skin mRNA expression levels of gremlin-1 (GREM-1), and interleukin (IL)-6 which may induce GREM-1, there was no significant difference between the groups. n = 7 in each group. Data are shown as mean ± SEM

Additional file 1 of Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis

Additional file 1. Experimental protocol. For induction of skin fibrosis, 8-week-old female Balb/c mice were subcutaneously injected with 100 μg/100 μL of bleomycin daily for 3 weeks. mASCs were administered 1 week after the start of bleomycin administration and evaluated at 3 weeks. mASCs: mouse adipose-derived mesenchymal stem cells